The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Cancer
Autors principals: Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2016
Matèries:
Cancer Genetics and Epigenetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5049644/
https://ncbi.nlm.nih.gov/pubmed/26314551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29825
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars